<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html>
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<title>Breast IHC and DISH</title>
<link rel="stylesheet" type="text/css" href="view.css" media="all">
<script type="text/javascript" src="view.js"></script>
<script>
function updateDescription (frm) 
{
    var Template = ""


if (frm.A01.value !== ""){
	Template += "- Estrogen receptor: " + frm.A01.value + "\n";
}

if (frm.A02.value !== ""){
	Template += "  - Intensity: " + frm.A02.value + "\n";
}

if (frm.A03.value !== ""){
	Template += "  - Positive nuclei(%) : " + frm.A03.value + "\n";
}

if (frm.A04.value !== ""){
	Template += "- Progesterone receptor: " + frm.A04.value + "\n";
}

if (frm.A05.value !== ""){
	Template += "  - Intensity: " + frm.A05.value + "\n";
}

if (frm.A06.value !== ""){
	Template += "  - Positive nuclei(%) : " + frm.A06.value + "\n";
}

if (frm.A07.value !== ""){
	Template += "- HER2/neu oncoprotein IHC: " + frm.A07.value + "\n";
}

if (frm.A08.value !== ""){
	Template += "  - Score : " + frm.A08.value + "\n";
}

if (frm.A25.value !== ""){
	Template += "  - Clustered Heterogeneity : " + frm.A25.value + "\n";
}

if (frm.A09.value !== ""){
	Template += "- HER2 DISH : " + frm.A09.value + "\n";
}

if (frm.A10.value !== ""){
	Template += "  - Number of tumor cell counted : " + frm.A10.value + "\n";
}

if (frm.A11.value !== ""){
	Template += "  - Average number of HER2 signals (black) per cell : " + frm.A11.value + "\n";
}

if (frm.A12.value !== ""){
	Template += "  - Average number of CEP17 signals (red) per cell : " + frm.A12.value + "\n";
}

if (frm.A13.value !== ""){
	Template += "  - HER2/CEP17 ratio : " + frm.A13.value + "\n";
}

if (frm.A26.value !== ""){
	Template += "  - Percentage of Cells with Amplified HER2 Signals : " + frm.A26.value + "\n";
}

if (document.getElementById("A14").checked || document.getElementById("A15").checked){
	Template += "  - Other ISH abnormalities: "  + "\n";
}

if (document.getElementById("A14").checked){
	Template += frm.A14.value + "\n";
}

if (document.getElementById("A15").checked){
	Template += frm.A15.value + "\n";
}

if (frm.A16.value !== ""){
	Template += "- Proliferation index Ki67 (%) : "+ frm.A16.value + "\n";
}


if (frm.A28.value !== ""){
	Template += "\n" + "- Cold ischemia time : " + frm.A28.value + " min";
} else {
		Template += "\n" + "- Cold ischemic time is uncertain." ;
}

if (frm.A28.value <= 60 && frm.A28.value !== ""){
		Template += "\n" + "  - Optimal (<= 60 min)." ;
}

if (frm.A28.value > 60  && frm.A28.value !== ""){
		Template += "\n" + "  - Prolonged intervals (> 60 min)." ;
}

if (frm.A27.value !== ""){
	Template += "\n" + "- Fixation time in buffered formalin : " + frm.A27.value + " hours";
}else {
		Template += "\n" + "- Formalin fixation time is uncertain." ;
}

if (frm.A27.value < 6  && frm.A27.value !== ""){
		Template += "\n" + "  - Inadequate fixation (<6 hours)." ;
}

if (frm.A27.value >= 6 && frm.A27.value <= 72 && frm.A27.value !== ""){
		Template += "\n" + "  - Optimal fixation (6-72 hours)." ;
}

if (frm.A27.value > 72  && frm.A27.value !== ""){
		Template += "\n" + "  - Prolonged intervals (>72 hours)." ;
}

if (frm.A28.value !== "" && frm.A28.value <= 60 && frm.A27.value >= 6 && frm.A27.value <= 72){
	Template += "\n" + "- Meet requirements specified in the latest version of the ASCO/CAP guidelines." + "\n"  ;
} else if (frm.A28.value == "" || frm.A27.value == ""){
	Template += "\n" + "- Given the uncertain cold ischaemia time and/or uncertain fixation time, please interpret the above results with caution." + "\n" ;
} else if (frm.A28.value > 60 || frm.A27.value < 6 || frm.A27.value > 72){
	Template += "\n" + "- Given the suboptimal cold ischaemia time and/or suboptimal formalin fixation time, please interpret the above results with caution." + "\n" ;
} 

if (frm.A29.value !== ""){
	Template += "- Test type : " + frm.A29.value + "\n";
}

if (frm.A19.value !== ""){
	Template += "\n" + "- Additional notes: " + "\n" + "  - " + frm.A19.value + "\n";
}

if (frm.A01.value + frm.A04.value !== ""){
	Template += "\n" + "Formalin-fixed paraffin embedded sections were assessed by IHC technique for ER and PR, using Novocastra ER (clone: 6F11) and Dako PR (clone: PgR636) with the Bond polymer refined detection system." + "\n";
}

if (frm.A07.value !== ""){
	Template += "\n" + "Formalin-fixed paraffin embedded sections were assessed by IHC technique for HER2, using Ventana monoclonal HER2/neu (4B5) with Ventana BenchMark ULTRA multimer detection system." + "\n";
}

if (frm.A09.value !== ""){
	Template += "\n" + "HER2 Dual ISH was performed on formalin-fixed paraffin embedded section with the Ventana INFORM HER2 Dual ISH DNA Probe Cocktail Assay on an automated system, and was examined by a pathologist under light microscopy." + "\n";
}

if (frm.A01.value == "Negative, Internal control cells absent"){
	Template += "\n" +  "No internal controls are present, but external controls are appropriately positive. If needed, testing another specimen that contains internal controls may be warranted for confirmation of ER status." + "\n";
}

if (frm.A01.value == "Low Positive (1-10% positive nuclei)"){
	Template += "\n" +  "The cancer in this sample has a low level (1-10%) of ER expression by IHC. There are limited data on the overall benefit of endocrine therapies for patients with low level (1-10%) ER expression, but they currently suggest possible benefit, so patients are considered eligible for endocrine treatment. There are data that suggest invasive cancers with these results are heterogeneous in both behavior and biology and often have gene expression profiles more similar to ER negative cancers." + "\n";
}

if (frm.A07.value == "Positive for over-expression" ||
	frm.A09.value == "Positive (HER2 gene is amplified)" ||
    frm.A09.value == "Positive (amplified, Group 1 result in greater than 10% of cell population)" ||
	frm.A09.value == "Positive, Group 2 ISH result (with IHC 3+)" ||
    frm.A09.value == "Positive, Group 3 ISH result (with IHC 2-3+)" ||
	frm.A09.value == "Positive, Group 4 ISH result (with IHC 3+)"){
	Template += "\n" +  "Patients with breast cancers that are HER2 IHC 3+ or IHC 2+/ISH amplified may be eligible for several therapies that disrupt HER2 signaling pathways."+ "\n";
}

if (frm.A07.value == "Negative for over-expression" ||
    frm.A07.value == "Equivocal for over-expression" ||
    frm.A07.value == "HER2-low (IHC 1+ or IHC 2+ & DISH-)" ||
	frm.A07.value == "HER2-ultra-low (faint/barely perceptible and incomplete staining in <10% of tumor cells without amplification on FISH)" ){
	Template += "\n" +  "Invasive breast cancers that test 'HER2-negative' (IHC 0, 1+ or 2+/ISH not-amplified) are more specifically considered 'HER2-negative for protein overexpression/gene amplification' since non-overexpressed levels of the HER2 protein may be present in these cases." + "\n" + "\n" + "Patients with breast cancers that are HER2 IHC 1+ or IHC 2+/ISH not-amplified may be eligible for a treatment that targets non-amplified/non-overexpressed levels of HER2 expression for cytotoxic drug delivery (IHC 0 results do not result in eligibility currently)."+ "\n";
}

if (frm.A09.value == "Negative, Group 2 ISH result (with IHC 0-2+)" || frm.A09.value == "Positive, Group 2 ISH result (with IHC 3+)"){
	Template += "\n" +  "This sample has a Group 2 HER2 ISH result (ratio greater than or equal to 2.0; less than 4.0 HER2 signals / cell). Evidence is limited on the efficacy of HER2-targeted therapy in the small subset of cases with HER2 / CEP17 ratio greater than or equal to 2.0 and an average HER2 copy number less than 4.0 / cell. In the first generation of adjuvant trastuzumab trials, patients in this subgroup who were randomized to the trastuzumab arm did not appear to derive an improvement in disease free or overall survival, but there were too few such cases to draw definitive conclusions. IHC expression for HER2 should be used to complement ISH and define HER2 status. If IHC result is not 3+ positive, it is recommended that the specimen be considered HER2 negative because of the low HER2 copy number by ISH and lack of protein overexpression."+ "\n";
}

if (frm.A09.value == "Negative, Group 3 ISH result (with IHC 0-1+)" || frm.A09.value == "Positive, Group 3 ISH result (with IHC 2-3+)"){
	Template += "\n" +  "This sample has a Group 3 HER2 ISH result (ratio less than 2.0; greater than or equal to 6.0 HER2 signals / cell). There are insufficient data on the efficacy of HER2-targeted therapy in cases with HER2 ratio less than 2.0 in the absence of protein overexpression because such patients were not eligible for the first generation of adjuvant trastuzumab clinical trials. When concurrent IHC results are negative (0 or 1+), it is recommended that the specimen be considered HER2 negative."+ "\n";
}

if (frm.A09.value == "Negative, Group 4 ISH result (with IHC 0-2+)" || frm.A09.value == "Positive, Group 4 ISH result (with IHC 3+)"){
	Template += "\n" +  "This sample has a Group 4 result (ratio less than 2.0; greater than or equal to 4.0 and less than 6.0 HER2 signals / cell). It is uncertain whether patients with greater than or equal to 4.0 and less than 6.0 average HER2 signals / cell and HER2 / CEP17 ratio less than 2.0 benefit from HER2 targeted therapy in the absence of protein overexpression (IHC 3+). If the specimen test result is close to the ISH ratio threshold for positive, there is a high likelihood that repeat testing will result in different results by chance alone. Therefore, when IHC results are not 3+ positive, it is recommended that the sample be considered HER2 negative without additional testing on the same specimen."+ "\n";
}
frm.holdtext.value = Template;
}


function CopyToClipboard() {
  /* Get the text field */
  var copyText = document.getElementById("holdtext");

  /* Select the text field */
  copyText.select();

  /* Copy the text inside the text field */
  document.execCommand("copy");

  /* Alert the copied text */
  alert("Report copied to clipboard");
}
</script>
<style>
table, th, td {
  border: 1px solid silver;
  border-collapse: collapse;
  padding: 4px;
}
</style>
</head>

<body>
<img id="top" src="top.png" alt="">
	<div id="form_container">
	<div class="form_description">
		<h2>
		<a href=".\cap\Cancer-Protocols-2025-06-Update\Breast Protocol Folder\Breast.Bmk_1.6.1.0.REL.CAPCP.pdf" target="_blank">
		<div class="tooltip">Breast biomarkers testing
		<span class="tooltiptext">click to access further explanations in the original CAP template</span>
		</div>
		</a></h2>
	</div>
	
<form>
<p>
<fieldset style="border-color:#e6e6ff;">
	<legend> <label class="description"> Biomarkers assessments : </label></legend>


<!--
<p>
- For ER/PR, use Allred scoring for routine service.
<br>
<table>
<caption> CAP protocol (June-2021 updated):</caption>
<tr>
<td>ER assessment:</td>
<td>NEGATIVE: < 1% </td>
<td>POSITIVE: >10%; "LOW POSITIVE": 1-10% </td>
</tr>
<tr>
<td>PR assessment:</td>
<td>NEGATIVE: < 1% </td>
<td>POSITIVE: >10% </td>
</tr>
</table>
</p>
-->

<p>
<table border="1">
<col width="40%">

<tr>
<td rowspan="3" valign="top">
<label class="description">- Estrogen recepter (ER) IHC :</label>
</td>
<td>
	<select class="element select large"  ID="A01">
		<option value=""></option>
		<option value="Cannot be determined">Cannot be determined</option>
		<option value="Negative">Negative</option>
		<option value="Positive (Allred score >2)">Positive (Allred score >2)</option>
		<option value=""></option>
		<option value="Negative, Internal control cells present and stain as expected">Negative, Internal control cells present and stain as expected</option>
		<option value="Negative, Internal control cells absent">Negative, Internal control cells absent</option>
		<option value="Negative, other (specify):">Negative, other (specify):</option>
		<option value="Positive (>10% positive nuclei)">Positive (>10% positive nuclei)</option>
		<option value="Low Positive (1-10% positive nuclei)">Low Positive (1-10% positive nuclei)</option>
	</select>
</td>
</tr>
<tr>
<td align="right">
<label>- Intensity :</label>
	<select class="element select medium"  ID="A02">
		<option value=""></option>
		<option value="Negative (0)">Negative (0)</option>
		<option value="Weak staining (1)">Weak staining (1)</option>
		<option value="Moderate staining (2)">Moderate staining (2)</option>
		<option value="Strong staining (3)">Strong staining (3)</option>
	</select>
</td>
</tr>
<tr>
<td align="right">
<label>- Positive nuclei (%) :</label>
	<select class="element select medium"  ID="A03">
		<option value=""></option>
		<option value="None (0)">None    (0)</option>
		<option value="< 1% (1)">< 1%    (1)</option>
		<option value="1-10% (2)">1-10%   (2)</option>
		<option value="11-33% (3)">11-33%  (3)</option>
		<option value="34-65% (4)">34-65%  (4)</option>
		<option value="66-100% (5)">66-100% (5)</option>
</select>
</td>
</tr>

<tr>
<td  rowspan="3" valign="top">
<label class="description">- Progesterone recepter (PR) IHC :</label>
</td>
<td>
	<select class="element select large"  ID="A04">
		<option value=""></option>
		<option value="Cannot be determined">Cannot be determined</option>
		<option value="Negative">Negative</option>
		<option value="Positive (Allred score >2)">Positive (Allred score >2)</option>
		<option value=""></option>
		<option value="Negative, Internal control cells present and stain as expected">Negative, Internal control cells present and stain as expected</option>
		<option value="Negative, Internal control cells absent">Negative, Internal control cells absent</option>
		<option value="Negative, other (specify):">Negative, other (specify):</option>
		<option value="Positive (>10% positive nuclei)">Positive (>10% positive nuclei)</option>
	</select>
</td>
</tr>

<tr>
<td align="right">
<label>- Intensity :</label>
	<select class="element select medium"  ID="A05">
		<option value=""></option>
		<option value="Negative (0)">Negative (0)</option>
		<option value="Weak staining (1)">Weak staining (1)</option>
		<option value="Moderate staining (2)">Moderate staining (2)</option>
		<option value="Strong staining (3)">Strong staining (3)</option>
	</select></td>
</tr>

<tr>
<td align="right">
<label>- Positive nuclei (%) :</label>
<select class="element select medium"  ID="A06">
		<option value=""></option>
		<option value="None (0)">None    (0)</option>
		<option value="< 1% (1)">< 1%    (1)</option>
		<option value="1-10% (2)">1-10%   (2)</option>
		<option value="11-33% (3)">11-33%  (3)</option>
		<option value="34-65% (4)">34-65%  (4)</option>
		<option value="66-100% (5)">66-100% (5)</option>
</select>
</td>
</tr>

<tr>
<td>
<label class="description">- Ki67 Proliferation index % :</label>
</td>
<td>
<input type="text" ID="A16" class="element text large" size="40">
</td>
</tr>

<tr>
<td rowspan="3" valign="top">
<label class="description">- <a href=".\cap\PATHWAY anti-HER-2_neu (4B5) Rabbit Monoclonal Primary Antibody Interpretation Guide for Breast Cancer.pdf" target="_blank">HER2/neu oncoprotein IHC</a>:</label>
</td>
	<td><select class="element select large"  ID="A07">
		<option value=""></option>
		<option value="Cannot be determined">Cannot be determined</option>
		<option value="Negative for over-expression">Negative for over-expression</option>
		<option value="Equivocal for over-expression">Equivocal for over-expression</option>
		<option value="Positive for over-expression">Positive for over-expression</option>
		<option value=""></option>
		<option value="HER2-low (IHC 1+ or IHC 2+ & DISH-)">HER2-low (IHC 1+ or IHC 2+ & DISH-)</option>
		<option value="HER2-ultra-low (faint/barely perceptible and incomplete staining in <10% of tumor cells without amplification on FISH)">HER2-ultra-low (faint/barely perceptible and incomplete staining in <10% of tumor cells without amplification on FISH)</option>
	</select></td>
</tr>

<tr>
<td align="right">
<label>- Score :</label>
	<select class="element select medium"  ID="A08">
		<option value=""></option>
		<option value="No membrane staining detected (0 / absent membrane staining)">No membrane staining detected (0 / absent membrane staining)</option>
		<option value="Membrane staining that is incomplete and is faint / barely perceptible and in less than or equal to 10% of tumor cells (0+ / with membrane staining)">Membrane staining that is incomplete and is faint / barely perceptible and in less than or equal to 10% of tumor cells (0+ / with membrane staining)</option>
		<option value="Incomplete membrane staining that is faint / barely perceptible and in greater than 10% of tumor cells (Score 1+)">Incomplete membrane staining that is faint / barely perceptible and in greater than 10% of tumor cells (Score 1+)</option>
		<option value="Weak to moderate complete membrane staining observed in greater than 10% of tumor cells (Score 2+)">Weak to moderate complete membrane staining observed in greater than 10% of tumor cells (Score 2+)</option>
		<option value="Less than or equal to 10% of the cancer has circumferential staining that is complete and intense (3+) (heterogeneous, but very limited in extent; consider results of additional samples) (Score 2+)">Less than or equal to 10% of the cancer has circumferential staining that is complete and intense (3+) (heterogeneous, but very limited in extent; consider results of additional samples) (Score 2+)</option>
		<option value="Abundant cytoplasmic staining present, obscuring evaluation of membrane stain intensity (Score 2+)">Abundant cytoplasmic staining present, obscuring evaluation of membrane stain intensity (Score 2+)</option>
		<option value="Circumferential membrane staining that is complete, intense, and in greater than 10% of tumor cells (Score 3+)">Circumferential membrane staining that is complete, intense, and in greater than 10% of tumor cells (Score 3+)</option>
	</select></td>
</tr>

<tr>
<td align="right">
- Clustered Heterogeneity :
<input type="text" class="element text small" ID="A25" size="3"></td>
</tr>

<tr><td rowspan="7" valign="top">
<label class="description">- <a href=".\cap\wolff-et-al-2023-human-epidermal-growth-factor-receptor-2-testing-in-breast-cancer-asco-college-of-american.pdf" target="_blank">HER2/neu oncoprotein DISH</a> :</label>
<a href=".\Biomarker-DISH-calculator.html" target="_blank">HER2 DISH calculator</a>
<!--
<br>
<a href=".\cap\her2_dish.xlsx" target="_blank">DOWNLOAD AN EXCEL FILE</a>
-->
</td>
	<td><select class="element select large"  ID="A09">
		<option value=""></option>
		<option value="Cannot be determined">Cannot be determined</option>
		<option value="Negative (HER2 gene is not amplified)">Negative (HER2 gene is not amplified)</option>
		<option value="Positive (HER2 gene is amplified)">Positive (HER2 gene is amplified)</option>
		<option value=""></option>
		<option value="Negative (not amplified, Group 5 result)">Negative (not amplified, Group 5 result)</option>
		<option value="Negative, Group 2 ISH result (with IHC 0-2+)">Negative, Group 2 ISH result (with IHC 0-2+)</option>
		<option value="Negative, Group 3 ISH result (with IHC 0-1+)">Negative, Group 3 ISH result (with IHC 0-1+)</option>
		<option value="Negative, Group 4 ISH result (with IHC 0-2+)">Negative, Group 4 ISH result (with IHC 0-2+)</option>
		<option value="Positive (amplified, Group 1 result in greater than 10% of cell population)">Positive (amplified, Group 1 result in greater than 10% of cell population)</option>
		<option value="Positive, Group 2 ISH result (with IHC 3+)">Positive, Group 2 ISH result (with IHC 3+)</option>
		<option value="Positive, Group 3 ISH result (with IHC 2-3+)">Positive, Group 3 ISH result (with IHC 2-3+)</option>
		<option value="Positive, Group 4 ISH result (with IHC 3+)">Positive, Group 4 ISH result (with IHC 3+)</option>
	</select></td>
</tr>

<tr><td align="right">
- Number of tumor cells counted :
<input type="text" class="element text small" ID="A10" size="10"></td>
</tr>

<tr><td align="right">
- Average HER2 signals (black) per cell :
<input type="text" class="element text small" ID="A11" size="10"></td>
</tr>

<tr><td align="right">
- Average CEP17 signals (red) per cell :
<input type="text" class="element text small" ID="A12" size="10"></td>
</tr>

<tr><td align="right">
- HER2/CEP17 ratio :
<input type="text" class="element text small" ID="A13" size="10"></td>
</tr>
<tr>
<td align="right">
- Cells with Amplified Signals (%):
<input type="text" class="element text small" ID="A26" size="10"></td>
</tr>

<tr>
<td>- Other ISH abnormalities:<br>
	<input class="element checkbox" type="checkbox" id="A14" value="    - Aneusomy"><label  class="choice">Aneusomy</label>
	<input class="element checkbox" type="checkbox" id="A15" value="    - Heterogeneous signals"><label class="choice">Heterogeneous signals</label>
</td>
</tr>

</table>
</p>

</fieldset>
</p>

<p>
<fieldset style="border-color:#e6e6ff;">
	<legend> <label class="description"> <a href=".\cap\Cancer-Protocols-2022-06-Update\Breast Protocol Folder\Breast.Bmk_1.5.0.0.REL_CAPCP.pdf#page=8" target="_blank">Analytical details</a> : </label></legend>
<p>
<table border="1">
<col width="40%">

<tr>
<td>
<label class="description">- Cold ischemia time (min) :</label>
</td>
<td>
<input type="text" class="element text small" ID="A28" size="3">
min
</td>

<tr>
<td>
<label class="description">- Fixation time in buffered formalin :</label>
</td>
<td>
<input type="text" class="element text small" ID="A27" size="3">
hours
</td>

</tr>

<tr>
<td>
</td>
</tr>

<tr>
<td>
<label class="">+ Test type :</label>
</td>
<td>
	<select class="element select large" ID="A29">
		<option value=""></option>
		<option value="Laboratory-developed test (QMH, HK).">Laboratory-developed test (QMH, HK).</option>
		<option value="Food and Drug Administration (FDA) cleared (specify test / vendor):">Food and Drug Administration (FDA) cleared (specify test / vendor):</option>
		<option value="Laboratory-developed test (Non-U.S.-based health systems).">Laboratory-developed test, Non-U.S.-based health systems.</option>
		<option value="Laboratory-developed test (Health Canada Approved (specify test / vendor:).">Laboratory-developed test, Health Canada Approved (specify test / vendor):</option>
		<option value="Other (specify):">Other (specify):</option>
	</select>
</td>
</tr>

</table>
</p>
<p>
- Per review after 2024 CAP site inspection <br>
- Please fill in/estimate the cold ischemic time (in minutes) and formalin-fixation time (in hours).<br>
- Optimal cold ishemic time less than or equal to 60 min <br>
- Optimal formalin-fixation time 6-72 hours.
</p>
</fieldset>
</p>


<p align="center" >

<iframe width="517" height="470" frameborder="0" scrolling="no" src="https://1drv.ms/x/c/4e150ef5229d3792/UQSSN50i9Q4VIIBO_3UAAAAAAFkAjAfw58fM5U4?em=2&wdAllowInteractivity=False&AllowTyping=True&ActiveCell='HER2%20DISH'!C7&Item='HER2%20DISH'!A1%3AH22&wdHideGridlines=True&wdDownloadButton=True&wdInConfigurator=True&wdInConfigurator=True"></iframe>
<br>
<a href=".\Biomarker-DISH-calculator.html" target="_blank">HER2 DISH calculator</a><br>
<a href=".\cap\her2_dish.xlsx" target="_blank">DOWNLOAD THE EXCEL FILE</a>
</p>

<p align="center" >

<iframe width="453" height="277" frameborder="0" scrolling="no" src="https://1drv.ms/x/c/4e150ef5229d3792/UQSSN50i9Q4VIIBO71IBAAAAADGiu7lwQ89z-xk?em=2&wdAllowInteractivity=False&AllowTyping=True&ActiveCell='Sheet1'!C4&Item='Sheet1'!A1%3AD13&wdHideGridlines=True&wdDownloadButton=True&wdInConfigurator=True&wdInConfigurator=True"></iframe>
<br>
<a href=".\Biomarker-PDL1-calculator.html" target="_blank">PD-L1 calculator</a><br>
<a href=".\cap\PD-L1.xlsx" target="_blank">DOWNLOAD THE EXCEL FILE</a>
</p>


<p>
<fieldset style="border-color:#e6e6ff;">
	<legend> <label class="description"> <a href=".\cap\her2_breast_update_algorithms_2023.pdf" target="_blank">Dual probe ISH interpretation </a>: </label></legend>
- Group 1 = Ratio greater than or equal to 2.0 and greater than or equal to 4.0 HER2 signals / cell<br>
- Group 2 = Ratio greater than or equal to 2.0 and less than 4.0 HER2 signals / cell =<br>
- Group 3 = Ratio less than 2.0 and greater than or equal to 6.0 HER2 signals / cell <br>
- Group 4 = Ratio less than 2.0 and greater than or equal to 4.0 and less than 6.0 HER2 signals / cell<br>
- Group 5 = Ratio less than 2.0 and less than 4.0 HER2 signals / cell<br>
<br>

<fieldset style="border-color:#e6e6ff;">
	<legend> Negative :</legend>
- Group 5;<br>
- Group 4 and concurrent IHC 0-1+ or 2+;<br>
- Group 3 and concurrent IHC 0-1+; and <br>
- Group 2 and concurrent IHC 0-1+ or 2+;<br>
<br>
</fieldset>
<fieldset  style="border-color:#e6e6ff;">
	<legend> Positive : </legend>
- Group 1;<br>
- Group 2 and concurrent IHC 3+;<br>  
- Group 3 and concurrent IHC 2+ or 3+; and<br>
- Group 4 and concurrent IHC 3+ <br>	
<br>
</fieldset>
<br>
</fieldset>
</fieldset>
</p>

<p align="center">
<a href=".\cap\fmolb-09-834651-g001.jpg" target="_blank"><img src=".\cap\fmolb-09-834651-g001.jpg" alt="HER2 IHC" width="600"></a>
<br>
From <a href="https://doi.org/10.3389/fmolb.2022.834651"  target="_blank">Venetis et al Front. Mol. Biosci. 2022.</a>
</p>
<p>
In the DESTINY-Breast 04 and 06 trials, “HER2 low” was considered IHC Score 1+ or 2+ / ISH negative, and “HER2 ultralow” was HER2 IHC Score of 0 (pattern 0+) with membrane staining that is incomplete and faint / barely perceptible in less than or equal to 10% of tumor cells. Breast cancers with these staining patterns may be eligible for treatment with trastuzumab-deruxtecan in the metastatic setting (but those with no staining, IHC 0, are currently excluded)
</p>
<p>
HER2-low<br>
HER2 IHC 2+ AND HER2 DISH negative OR HER2 IHC 1+<br>
Tarantino P et al. 2020<br><br>
HER2 Ultra-low<br>
It is immunohistochemically characterized by faint/barely perceptible and incomplete staining in =<10% of tumor cells without amplification on FISH. <br>
</p>

<p>
<label class="description">- Additional notes :</label>
 <textarea ID="A19" class = "element textarea medium" style="border-color:grey;"></textarea> 
</p>



<br><br>
<input type="button" name="copyform" value="Check your Report" onclick="updateDescription(this.form)"/>
<br>
<TEXTAREA ID="holdtext" name="holdtext" class="textarea large" style="border-color:coral;"></TEXTAREA>

<br><br>
<!-- The button used to copy the text -->
<button onclick="CopyToClipboard()">Copy text to Clipboard</button>

<input type="reset" value="Reset Form" name="reset" style="float: right;">
</form>
<br>
<br>

<div id="footer">
Last upated 23-Jun-2025, based on Breast Biomarkers 1.6.1.0 Jun-2025</a>.<br>
html form was created on <a href="https://www.phpform.org">pForm</a>, <a href="https://www.w3schools.com/">W3 School</a>, <a href="https://stackoverflow.com/">StackOverflow</a>, and <a href="https://icons8.com">Icons8</a>.<br><br>
Anatomical Pathology Division, Queen Mary Hospital, Hong Kong.
</div>
</div>
<img id="bottom" src="bottom.png" alt="">
</body>
</html>

